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1. Introduction 
Vitiligo is a common, acquired pigmentary disorder of unknown pathogenesis that presents 
a therapeutic challenge to many dermatologists (Figure 1). Although surgery in the form of 
grafting or transplantation is generally the most definitive treatment option, these 
procedures are limited by concerns of post-procedure cosmesis. Photochemotherapy using 
psoralen and ultraviolet A (PUVA) therapy, topical and oral immunosuppresants, as well as 
cosmetic camouflage are also commonly employed with varying clinical efficacy. 
Phototherapy is a popular treatment option, which includes both of the generalized 
ultraviolet B (UVB) therapies, broadband UVB (BB-UVB) and narrowband UVB (NB-UVB). 
The UVB-based therapeutic modalities in development are targeted delivery of BB- and NB-
UVB, monochromatic excimer light (MEL), microphototherapy, and combination therapy. In 
particular, the sophisticated devices that utilize MEL can emit coherent 308-nm radiation 
using the xenon chloride (XeCl) excimer laser or microphotography, while incoherent 
radiation can be supplied by various lamp and light systems. All of the UVB phototherapy 
modalities can be used in combination with topical or systemic agents, thus further 
expanding treatment options for vitiligo patients.  
2. History 
The use of ultraviolet (UV) irradiation was introduced into the field of dermatology in the 
1800s after its Nobel Prize-winning application in lupus vulgaris (Roelandts, 2002). By 1928, 
UV radiation was used in the Goeckerman regimen as part of the classic crude coal tar and 
phototherapy treatment for psoriasis. Decades later in 1978, BB-UVB phototherapy was 
developed and used for psoriasis and pruritus. NB-UVB originated in Europe in 1988 
indicated for psoriasis, and soon became widely used in the United States in the 1990s. Its 
innovative use in vitiligo came nearly a decade later in 1997 (Wiskemann 1978; Westerhof 
and Nieuweboer-Krobotova, 1997). The pivotal study introducing NB-UVB use in vitiligo 
demonstrated that more patients undergoing NB-UVB had repigmentation of vitiligo 
patches than those who underwent PUVA photochemotherapy (67% vs. 46%) (Westerhof 
and Nieuweboer-Krobotova, 1997). Since then, the use of UVB for vitiligo has become 
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commonplace, and new technologic developments in UVB therapy are continuously 
underway. The use of MEL with the excimer laser was first described in 1997 (Bonis, 
Kemeny et al., 1997).  
 
 
Fig. 1. Vitiligo of the hands.  
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Fig. 2. Near complete repigmention of vitiligo patches with NB-UVB treatment.  
3. Theory and mechanism of action 
UVB phototherapy consists of the use of artificial light without the use of adjunct 
photosensitizing agents. It is used for a variety of dermatological conditions, including 
psoriasis, atopic dermatitis and other eczematous disorders, pruritus, graft-versus-host-
disease, lichen planus, and seborrheic dermatitis, among others. In vitiligo, UVB 
phototherapy ideally results in repigmentation, disease control, and prevention of 
progression of vitiligo through its immunosuppressive and immunomodulatory properties. 
UVB is available for use in vitiligo as BB-UVB (290-320 nanometers, nm), NB-UVB (310-312 
nm), and monochromatic excimer light (MEL, 308 nm). Although the action spectrum or 
wavelength(s) specifically targeting vitiligo has yet to be determined, both BB- and NB-UVB 
as well as MEL have been demonstrated to be clinically effective.  
The mechanism of how UVB works in vitiligo is unknown. It is established that distinct 
UVB radiation wavelengths target particular chromophores in the skin, in particular 
keratinocytes and melanocytes in the epidermis and fibroblasts in the dermis, and facilitate 
the therapeutic mechanisms of the light depending on chromophore type and function. In 
the case of UVB, these include apoptosis induction, T-cell depletion, decreased antigen 
presentation, and the ability to regulate inflammatory mediators and cytokines (Novak, 
Bonis et al., 2002; Novak, Berces et al., 2004; Weichenthal and Schwarz, 2005). 
UV, in particular, NB-UVB, is presumed to stimulate dopa-lacking amelanotic melanocytes 
in the outer root sheaths of hair follicles to produce melanin (Cui, Shen et al., 1991; Norris, 
Horikawa et al., 1994). It also activates melanocyte migration to adjacent depigmented areas, 
causing perifollicular repigmentation (Cui et al., 1991; Norris et al., 1994). Furthermore, NB-
UVB and MEL (coherent and incoherent) were both found to upregulate endothelin-1 (ET-1) 
release from keratinocytes, which is thought to play a role in UVB-related melanocyte 
synthesis and migration (Noborio, Kobayashi et al., 2006). This action is directly dependent 
on UVB radiation dose, and may account for the particular effectiveness of the 308 nm and 
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310-312 nm wavelengths (Noborio, Kobayashi et al., 2006). Also, the 308 nm wavelength of 
MEL is most specific for lymphocyte DNA alteration (de With and Greulich, 1995). The 
quantitative induction of T-cell apoptosis is greater with excimer laser (MEL) than with 
conventional BB- or NB-UVB phototherapies. It is thought that the capability to induce T-
cell apoptosis is an indicator of clinical efficacy (Ozawa, Ferenczi et al., 1999). Furthermore, 
keratinocytes may be influenced to release other unidentified cytokines and factors, which 
suggests that UVB functions as an immunomodulator. This may support the theory of an 
autoimmune component in the pathogenesis of vitiligo. 
4. BB-UVB phototherapy 
Conventional BB-UVB phototherapy utilizes an artificial light source that emits in the 
radiation spectrum that extends from 280-320 nm (Cui, Shen et al., 1991; Norris, Horikawa et 
al., 1994). The pilot study of BB-UVB in vitiligo was reported in 1990, and observed that 57% of 
treated patients had excellent (>75%) repigmentation of vitiligo patches in a 52 week treatment 
period (Koster W, 1990). The investigators also noted its particular efficacy in facial lesions as 
well in skin types V and VI (Koster W, 1990). Little definitive evidence purports the use of BB-
UVB in vitiligo, primarily due to the dominant and successful use of NB-UVB. 
BB-UVB with vitamin supplementation was found to be effective in actively spreading vitiligo 
for inducing repigmentation when given 2-3 times weekly for 6-8 weeks (Don, Iuga et al., 
2006). Although the role of vitamin supplementation was not substantiated in the outcome, 
this particular trial suggests that BB-UVB can be an effective treatment for vitiligo (Don, Iuga 
et al., 2006). Targeted BB-UVB and MEL were found to have nearly equal rates and degrees of 
repigmentation when evaluated after 8 treatments (Asawanonda, Kijluakiat et al., 2008). 
Nearly 60% of patients had 80-100% repigmentation after 70 BB-UVB treatment sessions, a 
rate comparable to topical PUVA (55.6%) and NB-UVB (54.2%) treated patients in the same 
trial (El-Mofty, Mostafa et al., 2010). Other studies suggest that BB-UVB is less effective or 
had no effect compared to PUVA and NB-UVB phototherapy for the treatment of vitiligo 
(Hartmann, Lurz et al., 2005; Gawkrodger, Ormerod et al., 2008). Furthermore, targeted BB-
UVB therapy was found to have limited effectiveness in vitiligo, and treatment-responsive 
areas were limited to the face (Akar, Tunca et al., 2009).  
5. NB-UVB phototherapy 
NB-UVB phototherapy utilizes the 311-313 nm radiation spectrum, which excludes the shorter 
and more erythmogenic wavelengths of BB- and natural (sunlight) UVB. It has been shown to 
be more effective than PUVA photochemotherapy, without the adverse side effect profile of 
psoralen (Table 1) (Bhatnagar, Kanwar et al., 2007; Yones, Palmer et al., 2007). Evidence-based 
guidelines suggest that NB-UVB should be used instead of PUVA in both adult and pediatric 
patients who have treatment-resistant disease, widespread involvement (BSA > 10-20%), or 
disease that severely affects quality of life (Ostovari, Passeron et al., 2004; Gawkrodger, 
Ormerod et al., 2008; Silverberg, 2010). Furthermore, NB-UVB is suggested as the best choice for 
generalized disease, with topical immunomodulators (i.e., pimecrolimus cream or tacrolimus 
ointment) reserved for localized patches (Stinco, Piccirillo et al., 2009). Prognosis is significantly 
better in those with generalized vitiligo without acral involvement, and reportedly in females 
(El-Mofty, Mostafa et al., 2010). Less relevant predictors of clinical outcome include skin type, 
age, and previous response to phototherapy and other vitiligo treatments. 
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Table 1. NB-UVB Phototherapy Studies in Vitiligo 
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NB-UVB for vitiligo is most effective on the face and neck, followed by the trunk, and 
then upper extremities (Figure 3). Acral regions including the lower extremities, palms, 
and soles are more resistant to treatment. The reason has yet to be elucidated, but the 
regional density of hair follicles, which are reservoirs for melanocytes, are thought to play 
a role (Stinco, Piccirillo et al., 2009). In general, the repigmentation patterns in patients 
treated with NB-UVB are, in descending order, perifollicular (51.3%), then marginal, 
diffuse, and combined (Yang, Cho et al., 2010). However, the marginal pattern was 
observed to be the most common when >75% repigmentation occurred by 12 weeks of 
treatment (Yang, Cho et al., 2010). 
 
 
Fig. 3. A patient with facial vitiligo was treated with NB-UVB phototherapy three times 
weekly. A. The patient prior to initiating treatment. The patient was then started at 200 mJ 
based on standard protocol for Fitzpatrick skin type III. B. The patient with notable 
repigmentation after treatment 56 at a dose of 1001 mJ. 
Patients should be counseled that, although these conventional phototherapies are quite 
effective for the head and neck region, they are less effective in the acral regions, which are 
commonly resistant areas, and in particular, the hands and feet. In addition, possible side 
effects, such as a predisposition to the development of skin malignancy, should be 
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discussed. Phototherapy is ideal in patients who cannot tolerate or have failed other vitiligo 
treatments, elderly and pediatric patients, pregnant or lactating patients, and those with 
renal or hepatic dysfunction. It does not require systemic photosensitizers as in PUVA or 
other photochemotherapies. Administration is less cumbersome than PUVA, without the 
use of uncomfortable special protective eyewear that PUVA requires.  
Home UVB therapy may be a valuable and convenient option for select patients. Patient-
reported outcomes for home NB-UVB therapy and outpatient NB-UVB therapy revealed 
that they show similar clinical efficacy and safety profiles (Wind, Kroon et al., 2010). Home 
NB-UVB is convenient and can be cost-effective in certain situations. However, more reliable 





Fig. 4. A. Extensive vitiligo of the lower abdomen and hips. B. Repigmentation of vitiligo 
patches after 24 months of NB-UVB treatment.  
6. Conventional UVB phototherapy administration and dosing 
UVB phototherapy dosing is tailored to patient phototype (skin type). Other considerations 
include which and how much body surface area (BSA) is involved, the need for 
photoprotection of sensitive body areas such as the eyes or genitals, history of 
photosensitivity, use of photosensitizing drugs, previous UV irradiation history, and body 
surface area involvement, among other parameters. Both BB- and NB-UVB treatments are 
given in large whole-body chambers or cabins furnished with the designated high-intensity 
(BB-or NB-UVB) light tubes. NB-UVB should ideally occur three times a week with at least 
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24 hours (nonconsecutive days) in between treatments. The duration of treatment is often 
many months, and may be tapered down with time.  
For both BB-UVB and NB-UVB, the starting, or induction, dose must be determined, which 
is generally the minimal erythema dose (MED). Then, between 50-70% of this MED, or 
erythmogenic dose, is used. After initial treatment, doses are increased by 5-20% of the 
previous dose if patient tolerates treatment without phototoxicity or pruritus. The MED may 
be difficult to determine in vitiligo due to small lesion sizes and the tedious testing process 
to determine MED. For NB-UVB treatment of vitiligo, patients can also be assumed to have 
Fitzgerald skin type I lesional skin, which has an MED of 400 millijoules per centimeters 
squared (mJ/cm2) and further dosing is determined from this number.  
The treatment cap for number of treatments that Fitzpatrick skin types I-III may receive is 
arbitrarily set at 200 treatments. While there is no set limit for skin types IV-VI, the 
recommendation for number of treatments should be based on clinician discretion and 
patient consent (Gawkrodger, Ormerod et al., 2008). However, treatment caps have yet to be 
defined but based on our experience, long-term NB-UVB is safe. In children, disease control 
and repigmentation is achieved with biweekly treatments for 12 weeks and continues for 12 
months. At this point, 80% of pediatric patients have stabilization of disease (Silverberg, 
2010). Serial photography is recommended every 2-3 months to monitor disease progress, 
failure to respond, and safety, according to well-developed protocols for adults 
(Gawkrodger, Ormerod et al., 2008). 
For NB-UVB, the dosing protocol the authors recommend from decades of use in a 
dedicated academic phototherapy center, skin type is always assumed to be Type I, with 
initial dosing at 170 mJ, then increasing by 30 mJ at a time as tolerated. Missed treatments 
require dosage adjustment depending on number of days or weeks missed (Table 2). 
 
 
Number of Missed Days Dosage Adjustment 
1-7 Increase per skin type I 
8-11 Hold dose constant 
12-20 Decrease by 25% 
21-27 Decrease by 50% 
28 or more Start over 
 
Table 2. NB-UVB Dosage Adjustments for Missed Treatment Days 
Monitoring for side effects is crucial. The patient may report symptoms including burning, 
tightness, pruritus, and pain, among other phototoxicity-related complaints. The clinician 
may notice erythema or exacerbation of disease on physical examination. Focal erythema 
and tenderness can be managed by shielding affected areas until symptoms remit. The 
development of marked pain or blistering is an indication to reduce the previous dose of 
radiation by 25% and subsequently cautiously increasing dosage when there is no further 
adverse reaction.  
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Fig. 5. Amelanotic patches of vitiligo in flexural areas undergoing involution NB-UVB therapy.  
7. Monochromatic excimer light (MEL) 
Xenon-chloride excimer (excited dimer) light is composed of the specific 308 nm 
wavelength, creating monochromatic radiation that is known as monochromatic excimer 
light, or MEL. The dimers are a halide (xenon) and noble gas (chloride) combination, which 
creates a high-energy unstable state, which is then translated into light radiation. It is 
clinically useful in the treatment of vitiligo, as well as other inflammatory skin diseases such 
as psoriasis, as well as mycosis fungoides. Sources of MEL include lamps, handheld devices, 
and in-office systems. These all emit MEL as incoherent light, similar to conventional UVB 
phototherapy in that it is nonselective for body treatment area and is non-targeted (as 
opposed to the excimer laser).  
When a 308-nm MEL delivery system was used in vitiligo, half of lesions showed 
repigmentation at 2 weeks, and after an 8 week treatment period followed by a non-
treatment 5 week observation period, all patients maintained their respective degrees of 
improvement (Table 3) (Chimento, Newland et al., 2008). In general, patients who respond 
to MEL do so at the beginning, otherwise they do not respond at all (Leone, Iacovelli et al., 
2003). MEL has also successfully treated previously NB-UVB refractory disease, and has 
been shown to be more effective and quicker than conventional NB-UVB (Leone, Iacovelli et 
al., 2003; Le Duff, Fontas et al., 2010). In a head-to-head study in which patients served as 
their own controls, the 308-nm excimer laser and MEL lamp had similar efficacy, although 
the lamp induces more erythema (Le Duff, Fontas et al., 2010). In addition, the use of lower 
power density reduces the risk of adverse events. 
www.intechopen.com
 Vitiligo – Management and Therapy 78
 
Table 3. MEL Phototherapy Studies in Vitiligo 
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The advantage of MEL includes the ability to irradiate larger body surface areas rather than 
the confined target areas of lasers and that it can be used to treat the entire body at once. It 
can also be customized to treat certain patches, has the perks of shorter treatment times, 
frequency, and total treatment duration, which in turn can lead to increased patient 
compliance (Leone, Iacovelli et al., 2003).  
8. Excimer laser 
The use of laser (light amplification by stimulated emission of radiation) technology in 
dermatology was introduced in the mid-1980s and has since been applied to vitiligo 
therapy. The specific 308 nm wavelength utilized by MEL also comes in a coherent, or 
targeted format, which is administered by laser.  
The excimer laser is a well-tolerated, effective treatment that induces quicker 
repigmentation than other forms of vitiligo therapy (Spencer, Nossa et al., 2002). It is 
thought to share a similar mechanism of action as other UVB therapies, as evidenced by 
treated vitiligo patches that undergo the same repigmentation patterns observed in 
conventional NB-UVB phototherapy (Yang, Cho et al., 2010). 
Vitiligo patch location and duration of disease are thought to be factors in the efficacy and 
response to excimer laser (Hofer, Hassan et al., 2005; Zhang, He et al., 2010). The face, neck, 
and to a lesser extent, the trunk, are more sensitive, or responsive, to laser treatment than 
more resistant areas which have been identified as the acral areas of the extremities and 
bony prominences (Ostovari, Passeron et al., 2004). Clinical outcome is dependent on the 
total number of laser treatments, not treatment frequency. However, repigmentation is 
induced quickest with increased frequency: optimal treatment occurs three times weekly, 
followed by twice weekly treatments (Hofer, Hassan et al., 2005; Shen, Gao et al., 2007). 
Once weekly treatment is also acceptable and effective, and may increase patient compliance 
due to decreased clinic visit frequency (Xiang, 2008). The 308-nm excimer laser is also 
effective and safe treatment for pediatric patients, in particular those with localized disease 
(Cho, Zheng et al., 2011).  
Compared with conventional NB-UVB phototherapy, the excimer laser is not only more 
efficacious, allowing for lower cumulative dosing and faster clearance, but also spares 
normal unaffected skin from carcinogenic UV radiation exposure. The laser light intensity 
is much greater than conventional NB-UVB phototherapy and its energy is emitted in 
nanoseconds (rather than minutes). It is suggested that the increased efficacy in inducing 
T-cell apoptosis allows for greater clinical efficacy of the laser than other conventional 
light therapies. 
Side effects are generally well-tolerated, and are usually due to phototoxicity, i.e., 
erythema, hyperpigmentation, erosions, and blisters (Housman, Pearce et al., 2004). 
Patients with Fitzpatrick skin type 1 may be prone to frequent blistering, especially with 
the usage of supra-erythmogenic laser therapy. Subsequent conservative dosing, may not 
achieve any more benefit than general UVB phototherapy regimens (Gattu, Pang et al., 
2010). In addition, it can be used for patients with phobia of the light box or phototherapy 
unit, and may be more tolerable for children (Lapidoth, Adatto et al., 2007). However, the 
excimer laser is currently limited to outpatient use, which requires frequent clinic visits 
over a short time duration, which can lead to low patient compliance (Kemeny, Csoma et 
al., 2010).  
www.intechopen.com
 Vitiligo – Management and Therapy 80
 
www.intechopen.com
 Ultraviolet B (UVB) Phototherapy in the Treatment of Vitiligo 81 
 
Table 4. Excimer Laser Phototherapy Studies in Vitiligo 
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9. Microphototherapy 
Focused microphototherapy was developed in 1999, and utilizes UVB light in the 280-315 
nm spectrum. This form of UVB therapy uses a dark-colored pad with perforations to focus 
light only on vitiligo patches using an optical fiber and hood. Its efficacy in vitiligo has 
shown promising results (Lotti, Menchini et al., 1999; Lotti, Tripo et al., 2009). Treatment 
protocol begins with daily treatment for a week, then tapered down to a few times a week, 
and finally, twice monthly. Half of patients show a moderate response to treatment, and a 
quarter of patients have excellent (>75%) repigmentation. However, focused 
microphototherapy is laborious, requiring expensive tools and training to perform the 
procedures. 
10. Combination therapy 
The UVB phototherapy modalities can be combined with other vitiligo treatments. These 
include combinations with topical preparations including immunomodulators such as 
pimecrolimus and tacrolimus, immunosuppresants such as corticosteroids, and vitamin D 
analogues. Systemic medications can also be part of combination therapy, and these include 
supplements such as antioxidants as well as systemic corticosteroids.  
10.1 Pimecrolimus 
Pimecrolimus is a calcineurin inhibitor and immunomodulator available as a cream. It is 
generally well-tolerated and safe for long-term use. This topical formulation is used once to 
twice daily on vitiligo patches. Pimecrolimus inhibits T cell activation; however, data on 
melanocyte function are lacking (Dawid, Veensalu et al., 2006). Although already useful as 
monotherapy, it is also able to enhance phototherapy efficacy. NB-UVB works better if 
combined with pimecrolimus 1% cream (64.3%) rather than photomonotherapy (25.1%) on 
facial lesions (Elgoweini and Nour El Din, 2009). Pediatric patients also tolerate this 
combination well, with excellent repigmentation on the face, and with varying degrees of 
effectiveness on all body parts (Elgoweini and Nour El Din, 2009). Side effects are tolerated 
well and generally limited to phototoxic effects such as mild discomfort, neurosis, and 
erythema. Furthermore, pimecrolimus may sometimes exacerbate symptoms after 
phototherapy, which include blistering and pruritus (Hui-Lan, Xiao-Yan et al., 2009).  
10.2 Tacrolimus 
Tacrolimus, like pimecrolimus, is a calcineurin inhibitor and immunomodulator in an 
ointment formulation that is used once to twice daily for vitiligo and is an option for long-
term management. It is empirically used in vitiligo due to its ability to increase 
melanocyte proliferation as well as stem cell factors, and down-regulate a number of 
interleukins, interferon-gamma, tumor necrosis factor-alpha, and granulocyte monocyte-
colony stimulating factor (Grimes, Soriano et al., 2002; Lan, Chen et al., 2005). Tacrolimus 
ointment (0.1%) and NB-UVB combination treatment is more effective than NB-UVB 
monotherapy and the effect of tacrolimus is dose-dependent (Nordal, Guleng et al., 2011). 
The efficacy of tacrolimus and excimer laser is also additive; repigmentation is achieved 
quicker with total lower cumulative laser dosage (Passeron, Ostovari et al., 2004). Side 
effects due to tacrolimus-phototherapy dual therapy include itching, formication, 
erythema, and soreness.  
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Either pimecrolimus or tacrolimus with UVB as combination therapy are best used in sun-
exposed areas due to better treatment outcomes with combination therapy than non-
exposed skin (Stinco, Piccirillo et al., 2009). There is a non-significant difference in efficacy 
between pimecrolimus and tacrolimus, although pimecrolimus may be slightly more 
effective due to its lipophilic properties that enable it to penetrate depigmented epidermis 
better than tacrolimus (Stinco, Piccirillo et al., 2009). 
10.3 Vitamin D analogues 
Calcipotriol, or calcipotriene, and tacalcitol are synthetic vitamin D3 (calcitriol) analogues 
which bind to vitamin D receptors in the epidermis and affect melanocyte and keratinocyte 
maturation. These receptors are also on T cells. Studies found that combination calcipotriol 
and NB-UVB therapy was not superior to NB-UVB alone (Ada, Sahin et al., 2005; Hartmann, 
Lurz et al., 2005). Similar findings were found when calcipotriene ointment and NB-UVB 
three times weekly were combined (Kullavanijaya and Lim, 2004). The combination of the 
308 nm excimer laser and calcipotriol also did not seem to be superior to excimer laser alone 
in a small trial in patients who served as their own controls (Goldinger, Dummer et al., 
2007). However, tacalcitol and 308 nm excimer laser treatment is superior to the laser alone; 
and allows for quicker improvement into vitiligo patches with lower cumulative dosing (Lu-
yan, Wen-wen et al., 2006). 
10.4 Corticosteroids  
Topical corticosteroids have some value in vitiligo treatment but with the high risk of side 
effects, most commonly skin atrophy, as well as striae, erythema, and absorption near the 
eyes which poses a risk for glaucoma candidates (Gawkrodger, Ormerod et al., 2008). They 
should be reserved for short-term (< 2 months) use only. Recalcitrant vitiligo of the face and 
neck may benefit from the combination of excimer laser phototherapy with topical 
hydrocortisone 17-butyrate cream.This was observed to have induce >75% repigmentation 
of vitiligo involvement in 3 months (Sassi, Cazzaniga et al., 2008). Systemic 
immunosuppression to prevent progression of vitiligo using oral corticosteroids is not 
recommended for treatment due to the high risk of side effects, although used by some 
clinicians for active or rapidly progressing vitiligo. Furthermore, the additive effect of oral 
steroids to either NB- or BB-UVB phototherapy is minimal (Rath, Kar et al., 2008). 
10.5 Vitamins & antioxidants 
Supplemental vitamins and minerals are popular remedies and adjuncts for vitiligo 
therapy. It is thought that there is a relationship between vitiligo pathogenesis and 
oxidative stress (Gawkrodger, Ormerod et al., 2008). In conjunction with vitamin C 
(500mg twice daily), vitamin B12 (1,000 micrograms twice daily), and folic acid (5 mg 
twice daily), BB-UVB had a significant clinically efficacious outcome in actively spreading 
vitiligo. Vitamin supplementation was used hypothetically and the investigators could 
only imply that BB-UVB could be effective for vitiligo and the role of vitamins was 
unclear (Don, Iuga et al., 2006).  
In combination with NB-UVB, oral vitamin E supplementation (400 IU) was shown to 
augment therapy by hypothetically preventing lipid peroxidation of melanocytes and 
reducing phototherapy-related erythema (Elgoweini and Nour El Din, 2009). The use of 
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vitamin A supplements has also been studied, but its use with NB-UVB is not supported 
(Elgoweini and Nour El Din, 2009).  
10.6 L-phenylalanine 
Phenylalanine (L-phenylalanine) supplementation is thought to supply precursors for melanin 
production. It is an essential amino acid that is the precursor to tyrosine in melanin synthesis 
by hydroxylation and thereby turns into melanin. Although naturally occurring in the diet, 
supplementation and UV radiation administration is said to have some clinical value in 
vitiligo without any reports of serious adverse effects (Schulpis, Antoniou et al., 1989).  
10.7 Pseudocatalase  
Pseudocatalase is a low molecular-weight manganese complex that serves as a substitute for 
naturally occurring catalase, which is thought to be inactivated in vitiligo by hydrogen 
peroxide accumulation in the epidermis. It is used in combination with UVB and 
climatotherapy, the latter which is the physical relocation of the patient to an area with a 
climate ideal or more suitable to a disease, in this case, vitiligo. Topically applied 
pseudocatalase and calcium used twice daily with twice weekly UVB phototherapy had a 
90% repigmentation rate in an uncontrolled clinical trial. Initial results were seen in 8-16 
weeks. In comparison to NB-UVB monotherapy, pseudocatalase and NB-UVB combination 
treatment showed clinically significant results, and was superior, with >75% of treatment 
sites with repigmentation vs. 70% in NB-UVB monotherapy (Schallreuter and Rokos, 2007). 
Side effects include pruritus, hyperhidrosis, and hyperpigmentation. 
10.8 Tetrahydrocurcuminoid 
Tetrahydrocurcuminoid (THC) is a derivative of curcumin (diferuloymethane) which is a 
compound collected from the roots of tumeric (Curcuma longa). Based on the theory of 
combatting oxidative stress as a treatment for vitiligo, curcumin was the anti-
inflammatory agent investigated. Curcumoid cream (with the main active ingredient 
being THC) applied twice daily along with targeted NB-UVB twice weekly had higher 
repigmentation scores than phototherapy alone, although this was not statistically 
significant (Asawanonda and Klahan, 2010).  
10.9 Khellin 
Khellin is a furanochromone (dimethoxy-4, 9 methyl-7 oxo-5 5-H-Furo [3,2-G]-4H 
chromone) that is chemically similar to psoralen, which is the basis of PUVA 
photochemotherapy. It is clinically safer and less damaging to cellular DNA than psoralen. 
Khellin stimulates melanocyte activation, proliferation, migration, and melanogenesis 
(Carlie, Ntusi et al., 2003). Compared with MEL monotherapy, combination MEL and 
topical khellin 4% ointment had more > 75% repigmentation rates than MEL alone (25% vs. 
56.25%) (Saraceno, Nistico et al., 2009). Response is best in acute patches of the face, neck, 
and knees (Saraceno, Nistico et al., 2009).  
10.10 Microphototherapy 
The use of 311-nm narrow-band microphototherapy has been augmented with tacrolimus 
0.1% ointment twice a day, pimecrolimus 1% cream twice a day, betamethasone 
dipropionate 0.05% cream twice a day, calcipotriol ointment 50 micrograms/gram twice a 
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day, and 10% l-phenylalanine cream twice a day. Of these combinations, the 311-nm 
narrow-band UVB microfocused phototherapy with 0.05% betamethasone dipropionate 
cream gives the best repigmentation rate. In the latter treatment, the only short-term side 
effect is skin atrophy due to the corticosteroid cream (Lotti, Buggiani et al., 2008).  
10.11 Surgery 
Surgery may be an option for vitiligo treatment for disease refractory to conventional 
medical treatment. The use of split-skin grafting consists of harvesting the epidermis and 
part of the dermis from a normally concealed donor site (such as the inner thigh) for use on 
a mechanically manipulated (e.g., via dermabrasion) recipient area. Use of the 308 nm 
excimer laser for 32 treatments that were initiated 2 weeks post-surgery had a 100% 
response rate in patients by the end of therapy. Follow-up after one year showed even 
greater improvement in recipient sites (Al-Mutairi, Manchanda et al., 2010). 
Punch grafting followed by use of NB-UVB also results in better cosmetic outcome of 
surgical sites, with repigmentation in the majority of cases (Lahiri, Malakar et al., 2006). It is 
thought that adjunctive NB-UVB is an efficient, safe, and cost-effective addition to surgical 
procedures for vitiligo. 
11. Adverse effects and long-term usage 
Short-term adverse effects related to UVB phototherapy are mostly related to phototoxicity 
which includes burning, pruritus, xerosis, pain, blistering, as well as increased susceptibility 
to cutaneous herpes simplex virus infections. These can be managed with early 
identification and topical corticosteroids as well as the judicious use of systemic steroids and 
anti-inflammatory agents in serious cases. Overaggressive treatment resulting in phototoxic 
reactions (i.e., erythema) can lead to koebnerization. 
Long-term UVB exposure is associated with photodamage and photoaging, and is a 
carcinogen with the potential to increase long-term risk of malignancy (Gonzaga, 2009). At 
baseline, vitiligo patients with Fitzpatrick skin types I and II have a non-statistically significant 
increased risk of nonmelanoma skin cancer than the general population; however, this is not 
reported in more pigmented skin types (type III and above) (Hexsel, Eide et al., 2009).  
In Caucasian-based population studies, PUVA is an established risk factor for NMSC, 
particularly with long-term therapy in patients with skin types I-II patients (Stern and Laird, 
1994). This risk has been appreciated as early as within a 2-year follow-up period (Stern and 
Laird, 1994). It is the strongest predictor of squamous cell carcinoma (SCC) risk, the latter of 
which is also influenced by male gender, having skin types I-II, residence in southern 
regions, as well as the use of high-dose methotrexate and/or cyclosporin (Lim and Stern, 
2005). PUVA only modestly increases BCC risk, which is also increased by male gender and 
exposure to high dose tar and/or methotrexate. NMSC due to PUVA use is modestly 
increased with high UVB exposure (>300 treatments) limited to less than 100 PUVA 
treatments, however these appear on usually non-sun exposed anatomic sites (Lim and 
Stern, 2005). However, the carcinogenic risk of PUVA in non-Caucasians, in particular, 
Asian and Arabian-African populations, is not substantiated (Murase, Lee et al., 2005). The 
analysis of the effect of ethnicity on PUVA risk of 4,294 long-term non-Caucasian PUVA 
patients with at least a 5-year follow-up implied that pigmented skin and ethnic skin types 
may confer photoprotection (Murase, Lee et al., 2005). Therefore, although the carcinogenic 
risks of PUVA therapy must be seriously considered in Caucasian vitiligo patients, vitiligo 
patients with skin of color may consider PUVA therapy with more assurance.  
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Table 5. Phototherapy Follow-up in Dermatology Patients and Carcinogenic Risk 
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When comparing UVB and PUVA carcinogenic risk, a single PUVA increases risk 7 times 
more than a single UVB treatment (Lim and Stern, 2005). Even with a history if PUVA therapy, 
patients who had less than 300 treatments of UVB had no appreciable increase in NMSC risk 
(Lim and Stern, 2005). Available data on NB-UVB therapy has not consistently identified a 
significant increase in NMSC when compared to the general population (Table 4). The majority 
of follow-up data was primarily taken from Caucasian populations, but the same conclusion 
has been drawn in non-Caucasians with skin types III-V (Jo, Kwon et al., 2010). An increased 
risk of BCC was noted in two Scottish studies, one with NB-UVB monotherapy, and the other 
with a history of both NB-UVB and PUVA usage (Stern and Laird, 1994; Man, Crombie et al., 
2005). However, the temporal relationship between tumor diagnosis and phototherapy makes 
a relationship between therapy and cancer unlikely in either study (Stern and Laird, 1994; 
Man, Crombie et al., 2005). In addition, it is common to use topical pimecrolimus and/or 
tacrolimus as adjuncts to NB-UVB. Topical pimecrolimus and tacrolimus have not been found 
to increase risk of NMSC in adults. Therefore, even in combination with NB-UVB, there should 
be no cumulative carcinogenic effect. Therefore, UVB, in particular NB-UVB, may be the 
phototherapy option with the least carcinogenic risk in all skin types.  
 
 
Fig. 6. NB-UVB is an effective treatment modality for vitiligo. Short term adverse effects are 
primarily related to phototoxicity. Long-term carcinogenic risk may not differ greatly from 
the general population.  
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Due to lack of long-term phototherapy research data specifically in vitiligo, it is difficult to 
wholly substantiate any claims regarding potential risk. Available phototherapy follow-up 
data was drawn from patients treated with a variety of photoresponsive dermatoses, which 
includes vitiligo, despite lack of quantification of vitiligo cases. Further research specifically 
on carcinogenic risk in vitiligo is needed. 
12. Conclusion 
Although multiple management options exist for vitiligo, UVB phototherapy is generally 
the treatment of choice as it is not only effective but has a favorable risk-to-benefit ratio. 
Conventional BB- and NB-UVB is widely available and useful particularly in widespread 
disease, although NB-UVB has been more extensively studied with proven efficacy. The 
development of MEL has provided options for both generalized and limited disease and is 
available in a variety of treatment systems. MEL has also been applied to laser therapy, 
which is growing in popularity due to the benefits of quicker treatment duration, increased 
efficacy, and a better risk-to-benefit ratio compared to conventional phototherapy 
techniques. Combination therapies are also useful and may provide quicker regimentation 
and treat vitiligo with an additive mechanism of action than UVB phototherapy. Advances 
in technology may lead to the continuing use of UVB phototherapy as a treatment for 
vitiligo through the development of sophisticated devices and delivery systems as well as 
innovative application methods. These will provide increased therapeutic options for all 
vitiligo patients, particularly those with refractory disease. 
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